GILD Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 15.22
- PEG ratio
- 2.14
- P/B
- 6.62
- P/S (TTM)
- 5.24
- EV/EBITDA
- 11.76
Profitability & growth
- ROE (TTM)
- 43.4%
- Operating margin
- 39.3%
- Revenue growth YoY
- 4.4%
- Dividend yield
- 2.5%
- Beta
- 0.33
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
36 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Gilead Sciences Inc
Company profileGilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 333 LAKESIDE DRIVE, FOSTER CITY, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
